Executive Summary
Latest Data: Sep 2025A large-scale business, operating profitably valued in line with the market.
Business Narrative
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
Company at a Glance
Business Performance
Key Highlights
Positive Signals
- Trading 26% below 5-year average valuation
Financial Health
Valuation Assessment
(-12%)
Valuation Corridor
Detailed Financials
Comprehensive financial statement data for deep analysis
| Metric | Sep 21 | Sep 22 | Sep 23 | Sep 24 | Sep 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 45.1% | 44.9%↓0.4% | 42.2%↓6.1% | 45.2%↑7.2% | 45.4%↑0.5% |
| Operating Margin | 11.8% | 12.1%↑2.8% | 10.9%↓9.9% | 11.9%↑9.0% | 11.8%↓0.6% |
| Net Margin | 10.9% | 9.4%↓13.8% | 7.7%↓18.7% | 8.4%↑10.3% | 7.7%↓9.1% |
| Earnings Yield | - | - | - | - | - |